145 related articles for article (PubMed ID: 38296547)
1. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer.
Tahara M; Takami H; Ito Y; Okamoto T; Sugitani I; Sugino K; Takahashi S; Takeyama H; Tsutsui H; Hara H; Mitsuma A; Yamashita H; Ohashi Y; Imai T
Thyroid; 2024 May; 34(5):566-574. PubMed ID: 38629757
[No Abstract] [Full Text] [Related]
3. Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Majid O; Hayato S; Sreerama Reddy SH; Lalovic B; Hihara T; Hoshi T; Funahashi Y; Aluri J; Takenaka O; Yasuda S; Hussein Z
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):954-969. PubMed ID: 38528813
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
[TBL] [Abstract][Full Text] [Related]
5. Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer.
Masaki C; Sugino K; Kobayashi S; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Int J Clin Oncol; 2020 Jul; 25(7):1278-1284. PubMed ID: 32347432
[TBL] [Abstract][Full Text] [Related]
6. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
7. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
9. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib.
Fages V; Jannin A; Maanaoui M; Glowacki F; Do Cao C
J Nephrol; 2024 Jan; 37(1):187-189. PubMed ID: 37418091
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
Zheng X; Xu Z; Ji Q; Ge M; Shi F; Qin J; Wang F; Chen G; Zhang Y; Huang R; Tan J; Huang T; Li S; Lv Z; Lin Y; Guo Z; Kubota T; Suzuki T; Ikezawa H; Gao M
Clin Cancer Res; 2021 Oct; 27(20):5502-5509. PubMed ID: 34326132
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
13. Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer.
Shibutani Y; Suzuki S; Sagara A; Enokida T; Okano S; Fujisawa T; Sato F; Yumoto T; Sano M; Kawasaki T; Tahara M
Front Oncol; 2023; 13():1154771. PubMed ID: 36998435
[TBL] [Abstract][Full Text] [Related]
14. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for Anaplastic Thyroid Cancer.
Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S
Front Oncol; 2017; 7():25. PubMed ID: 28299283
[TBL] [Abstract][Full Text] [Related]
16. A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
Fukuda N; Toda K; Udagawa S; Ohmoto A; Oki R; Suto H; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocrine; 2022 Apr; 76(1):70-77. PubMed ID: 35088293
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
[No Abstract] [Full Text] [Related]
18. Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma.
Hyogo Y; Kiyota N; Otsuki N; Goto S; Imamura Y; Chayahara N; Toyoda M; Nibu KI; Hyodo T; Hara S; Masuoka H; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Case Rep Oncol; 2018; 11(3):735-741. PubMed ID: 30519176
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients.
Fukuda N; Toda K; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2021 Jun; 68(6):639-647. PubMed ID: 33504716
[TBL] [Abstract][Full Text] [Related]
20. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
